Evolution of Hepatitis C Virus Quasispecies during Ribavirin and Interferon-Alpha-2b Combination Therapy and Interferon-Alpha-2b Monotherapy | Citedby Results | Intervirology | Karger Publishers

Skip to Main Content

Skip Nav Destination

Evolution of Hepatitis C Virus Quasispecies during Ribavirin and Interferon-Alpha-2b Combination Therapy and Interferon-Alpha-2b Monotherapy

Intervirology (2006) 49 (6): 352–361.

This article has been cited by the following articles in journals that are participating in CrossRef Cited-by Linking.

Host nutritional status affects alphavirus virulence, transmission, and evolution

James Weger-Lucarelli
Lucia Carrau
Laura I. Levi
Veronica Rezelj
Thomas Vallet
Hervé Blanc
Jérémy Boussier
Daniela Megrian
Sheryl Coutermarsh-Ott
Tanya LeRoith
Marco Vignuzzi
Richard J. Kuhn

PLOS Pathogens (2019) 15 (11): e1008089.

Synthesis and biological evaluation of novel anti-hepatitis C virus (HCV) agents: 2-hydroxylphenethyl sulfanyl-oxopyrimidines

Daochun Wu
Yue Feng
Hua Wang
Junfeng Yang
Xian Chen
Yueping Wang
Christopher Cong Lai
Yufang Zhang
Cong Li
Xueshan Xia
Yanping He

Medicinal Chemistry Research (2017) 26 (7): 1388.

Combined 3D‐QSAR, Molecular Docking, Molecular Dynamics Simulation, and Binding Free Energy Calculation Studies on the 5‐Hydroxy‐2H‐Pyridazin‐3‐One Derivatives as HCV NS5B Polymerase Inhibitors

Haijing Yu
Yu Fang
Xia Lu
Yongjuan Liu
Huabei Zhang

Chemical Biology & Drug Design (2014) 83 (1): 89.

Synthesis and SAR optimization of diketo acid pharmacophore for HCV NS5B polymerase inhibition

Aaditya Bhatt
K.R. Gurukumar
Amartya Basu
Maulik R. Patel
Neerja Kaushik-Basu
Tanaji T. Talele

European Journal of Medicinal Chemistry (2011) 46 (10): 5138.

Evolution of hepatitis B genotype C viral quasi-species during hepatitis B e antigen seroconversion

Shuang Wu
Fumio Imazeki
Fuat Kurbanov
Kenichi Fukai
Makoto Arai
Tatsuo Kanda
Yutaka Yonemitsu
Yasuhito Tanaka
Masashi Mizokami
Osamu Yokosuka

Journal of Hepatology (2011) 54 (1): 19.

Structure-based virtual screening, synthesis and SAR of novel inhibitors of hepatitis C virus NS5B polymerase

Tanaji T. Talele
Payal Arora
Shridhar S. Kulkarni
Maulik R. Patel
Satyakam Singh
Maksim Chudayeu
Neerja Kaushik-Basu

Bioorganic & Medicinal Chemistry (2010) 18 (13): 4630.

Characterization of Aurintricarboxylic Acid as a Potent Hepatitis C Virus Replicase Inhibitor

Ye Chen
Alain Bopda-Waffo
Amartya Basu
Ramalingam Krishnan
Erica Silberstein
Deborah R Taylor
Tanaji T Talele
Payal Arora
Neerja Kaushik-Basu

Antiviral Chemistry and Chemotherapy (2009) 20 (1): 19.

Ribavirin in the treatment of chronic hepatitis C

Paul Martin
Donald M Jensen

Journal of Gastroenterology and Hepatology (2008) 23 (6): 844.

Ribavirin mode of action in chronic hepatitis C: from clinical use back to molecular mechanisms

Wolf Peter Hofmann
Eva Herrmann
Christoph Sarrazin
Stefan Zeuzem

Liver International (2008) 28 (10): 1332.

Resistance mechanisms in HCV: from evolution to intervention

Arthur Y Kim
Joerg Timm

Expert Review of Anti-infective Therapy (2008) 6 (4): 463.

Hepatitis C Virus Diversity and Evolution in the Full Open-Reading Frame during Antiviral Therapy

Nathan A. Cannon
Maureen J. Donlin
Xiaofeng Fan
Rajeev Aurora
John E. Tavis
Sheila Mary Bowyer

PLoS ONE (2008) 3 (5): e2123.

Analysis of Ribavirin Mutagenicity in Human Hepatitis C Virus Infection

Stéphane Chevaliez
Rozenn Brillet
Ester Lázaro
Christophe Hézode
Jean-Michel Pawlotsky

Journal of Virology (2007) 81 (14): 7732.